Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention Pharmaceutical TechnologyThe benefits of intensive LDL-C lowering with Repatha (evolocumab) may extend beyond cardiovascular event prevention to reducing mortality.CardiovascularRead full story pharminent August 31, 2026 (Last updated: September 1, 2026) Pharmaceutical Technology The benefits of intensive LDL-C lowering with Repatha (evolocumab) may extend beyond cardiovascular event prevention to reducing mortality. Cardiovascular Read full story Post navigation Previous: Acquisitive Lilly offers $2.88bn for Merida BioNext: Lilly Pays Up to $2.875 Billion for Merida and a Phase 1 Autoantibody Platform Related Stories Clinical Data Spyre deprioritises arthritis drug after Phase 2 results pharminent August 26, 2026 Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026
